While the United States continues making sweeping changes to its vaccination recommendations, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccines throughout the global health crisis and has focused upon possible deaths following Covid vaccination in her recent position at the Food and Drug Administration.
Agency leaders had intended to unveil major revisions to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of step with a large portion of the global community with insufficient data for improved outcomes. The planned update has been pushed back until the new year.
Instead of the director of the vaccine center, Dr. Høeg is scheduled to present at the event. She was recently named acting director of the FDA’s CDER, the fifth individual to head the center this year.
Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon dismantling previously authorized vaccines at the FDA.
Høeg has repeatedly called for discontinuing specific childhood vaccine recommendations in the US to become more in line with Denmark, a nation with comprehensive healthcare and a population approximately the size of the state of Wisconsin.
In her initial public appearances, she has persisted in emphasizing on immunizations – traditionally the purview of Prasad, chief of the FDA’s vaccine center – rather than pharmaceutical oversight.
Høeg has no apparent experience in medication creation, approval processes or administrative roles, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since March.
“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a large organization. She lacks background in industry regulation.”
Former directors of CBER would “understand regulatory frameworks and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that previous people who headed CBER have had.”
The drug center has an immense range of responsibilities at the FDA, she pointed out.
“Many people just pays attention on the innovative therapies, but the generic program approves thousands of generic medications. There is also a biosimilars program, OTC medication office and so forth, and each of these have to be supervised,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”
Furthermore, a significant administrative aspect to the position, which manages over 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” Woodcock said.
In response to questions about Høeg’s fitness for the role and whether this assignment indicates more teamwork among FDA leaders on immunizations, a press secretary responded that the “concerns rely on inaccurate premises”.
“Her experience matches the functions of her position,” the representative stated, pointing to the time Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.
In her interim role, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a controversial expedited therapy clearance system that apparently worried her predecessors. “By what process are these medications being picked for this voucher program? Who is making the choices?” Howard questioned. “There is a lot of secrecy happening at the regulatory body right now.”
Overall, he stated, “the Food and Drug Administration appears to be shifting towards less stringent rules of pharmaceuticals, except for vaccines.”
Regarding vaccines, Høeg has a more documented, if problematic, past, Howard have noted. She published a study using unverified volunteer-provided data to assess the incidence of heart inflammation following COVID-19 immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccines are more dangerous than they are.
Among her “policy goals” for the current federal leadership encompassed altering rules for novel immunizations and halting “non-essential” vaccines, she remarked after the election on a audio program. At the FDA, Høeg has reportedly suggested barring teenage boys from receiving COVID-19 vaccines.
“She’s an all-around true believer who commences with her preconceived notions and works backwards to accommodate the science in a highly disingenuous, dishonest manner,” Howard stated.
Høeg became part of fellow contrarians, {like|
